Headlines about CareDx (NASDAQ:CDNA) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned news stories about the company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
CareDx (CDNA) traded down 0.7333% during trading on Tuesday, hitting $1.3401. 22,027 shares of the stock were exchanged. The firm’s market capitalization is $28.71 million. CareDx has a 12-month low of $0.76 and a 12-month high of $5.06. The stock has a 50 day moving average price of $1.23 and a 200-day moving average price of $1.52.
A number of research firms have weighed in on CDNA. Zacks Investment Research raised CareDx from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. ValuEngine downgraded shares of CareDx from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
ILLEGAL ACTIVITY WARNING: This article was reported by BBNS and is the property of of BBNS. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/caredx-cdna-earning-somewhat-positive-press-coverage-accern-reports-updated-updated-updated/1196508.html.
In related news, major shareholder Neil Gagnon bought 63,120 shares of the company’s stock in a transaction on Friday, June 23rd. The stock was acquired at an average cost of $1.10 per share, for a total transaction of $69,432.00. Following the completion of the transaction, the insider now directly owns 886,216 shares in the company, valued at approximately $974,837.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired 80,689 shares of company stock valued at $87,815 in the last quarter. Company insiders own 5.40% of the company’s stock.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with our FREE daily email newsletter.